(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 8.92%
@ $3.53
发出时间: 14 Feb 2024 @ 05:00
回报率: -29.46%
上一信号: Feb 13 - 22:30
上一信号:
回报率: -2.22 %
Live Chart Being Loaded With Signals
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States...
Stats | |
---|---|
今日成交量 | 783 203 |
平均成交量 | 891 956 |
市值 | 330.10M |
EPS | $0 ( 2024-02-29 ) |
下一个收益日期 | ( $-0.0300 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 62.25 |
ATR14 | $0.00600 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Cavorsi Robert | Sell | 0 | Class A Common Stock |
2024-04-19 | Cavorsi Robert | Sell | 0 | Class A Common Stock |
2024-04-19 | Cavorsi Robert | Sell | 0 | Class A Common Stock |
2024-04-19 | Cavorsi Robert | Sell | 0 | Class A Common Stock |
2024-04-19 | Cavorsi Robert | Sell | 0 | Class A Common Stock |
INSIDER POWER |
---|
72.76 |
Last 100 transactions |
Buy: 10 063 749 | Sell: 1 162 734 |
音量 相关性
Organogenesis Holdings 相关性 - 货币/商品
Organogenesis Holdings 财务报表
Annual | 2023 |
营收: | $433.14M |
毛利润: | $309.79M (71.52 %) |
EPS: | $0.0377 |
FY | 2023 |
营收: | $433.14M |
毛利润: | $309.79M (71.52 %) |
EPS: | $0.0377 |
FY | 2022 |
营收: | $450.89M |
毛利润: | $345.87M (76.71 %) |
EPS: | $0.120 |
FY | 2021 |
营收: | $468.06M |
毛利润: | $353.86M (75.60 %) |
EPS: | $0.740 |
Financial Reports:
No articles found.
Organogenesis Holdings
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。